SLS
SELLAS Life Sciences Group Inc.
$9.18
+$0.60(+6.99%)
48
Overall
40
Value
70
Tech
36
Quality
Market Cap
$1.63B
Volume
10.14M
52W Range
$1.39 - $9.10
Target Price
$10.00
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | -- | -- | -- | $1.9M | $7.6M | $1.0M | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | -- | $1.9M | $7.6M | $1.0M | -- | -- | -- | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | $-5.2M | -- | -- | -- | $200.0K | $100.0K | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | $5.2M | -- | -- | $1.9M | $7.4M | $900.0K | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $31.9M | $23.0M | $25.3M | $17.2M | $18.9M | $27.0M | $32.9M | $37.9M | $31.5M | $28.3M | ||
| Research & Development | $11.4M | $6.1M | $8.8M | $7.3M | $9.3M | $15.7M | $30.3M | $24.0M | $19.1M | $16.0M | ||
| Research Expense | $11.4M | $6.1M | $8.8M | $7.3M | $9.3M | $15.7M | $20.3M | $24.0M | $19.1M | $16.0M | ||
| Selling, General & Administrative | $4.6M | $15.1M | $12.8M | $9.9M | $9.6M | $11.3M | $12.6M | $13.9M | $12.4M | $12.3M | ||
| Selling & Marketing Expenses | $4.6M | $15.1M | $12.8M | $9.9M | $9.6M | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-200.0K | $-200.0K | $-300.0K | $-400.0K | $9.6M | $11.3M | $12.6M | $13.9M | $12.4M | $12.3M | ||
| Salaries & Wages | $-354.0K | $-3.2M | $-395.0K | $-573.0K | $-578.0K | -- | -- | $2.1M | -- | -- | ||
| Depreciation & Amortization | $-142.0K | $1.9M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-142.0K | $1.9M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Amortization | -- | $1.9M | -- | -- | $2.2M | $3.0M | $1.9M | $1.9M | $1.9M | -- | ||
| Other Operating Expenses | $12.0M | $-28.0K | $3.8M | $586.0K | $95.0K | $300.0K | $500.0K | $500.0K | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-16.0M | $-23.0M | $-25.3M | $-17.2M | $-17.0M | $-25.3M | $-42.0M | $-37.9M | $-31.5M | $-28.3M | ||
| EBITDA | $-10.9M | $-23.2M | $-29.0M | $-38.9M | $-16.8M | $-20.9M | $-31.9M | $-36.8M | $-31.0M | $-27.8M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $-118.0K | $-26.0K | $-6.0K | $-317.0K | $-525.0K | $-632.0K | $-1.4M | ||
| Intinc | $18.7M | -- | -- | -- | -- | -- | -- | $525.0K | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $18.7M | -- | -- | $118.0K | $26.0K | $6.0K | $-317.0K | $525.0K | $632.0K | $1.4M | ||
| Other Income/Expense | $526.0K | $-12.5M | $3.5M | $2.3M | $-182.0K | $1.3M | $-9.7M | $-4.0K | -- | -- | ||
| Other Special Charges | $-526.0K | -- | $6.1M | $550.0K | $182.0K | $4.4M | $332.0K | $4.0K | -- | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $-28.4M | $-1.9M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | $28.4M | $1.9M | -- | $-19.4M | -- | -- | -- | -- | -- | -- | ||
| Other Impairment Of Capital Assets | -- | -- | $9.6M | $2.8M | -- | $5.7M | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-10.9M | $-23.5M | $-29.0M | $-38.9M | $-16.8M | $-20.9M | $-31.9M | $-37.3M | $-31.5M | $-28.4M | ||
| Pre-Tax Income | $-10.9M | $-23.5M | $-29.0M | $-38.7M | $-16.8M | $-20.9M | $-41.3M | $-37.3M | $-30.9M | $-26.9M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $1.0K | $253.0K | $-1.4M | $-81.0K | $-17.0K | $-237.0K | -- | -- | -- | $-47.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-23.5M | $-23.8M | $-27.7M | $-38.7M | $-16.8M | $-20.7M | $-41.3M | $-37.3M | $-30.9M | $-26.9M | ||
| Net Income (Continuing Operations) | $-23.5M | $-23.8M | $-27.7M | $-38.7M | $-16.8M | $-20.7M | $-41.3M | $-37.3M | $-30.9M | $-26.9M | ||
| Net Income (Discontinued Operations) | $-23.5M | $-23.8M | $-27.7M | $-38.7M | $-16.8M | $-20.7M | $-41.3M | $-37.3M | $-30.9M | $-26.9M | ||
| Net Income (Common Stockholders) | $-17.7M | $-24.4M | $-41.3M | $-47.3M | $-16.8M | $-20.7M | $-41.3M | $-37.3M | $-30.9M | $-26.9M | ||
| Normalized Income | -- | -- | -- | -- | $-16.8M | $-15.5M | -- | -- | -- | $-26.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $31.9M | $17.8M | $25.3M | $17.2M | $18.9M | $27.2M | $33.0M | $37.9M | $31.5M | $28.3M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $6.6K | $46.8K | $261.5K | $2.6M | $8.0M | $15.5M | $19.4M | $27.8M | $61.2M | $109.1M | ||
| Average Shares Outstanding (Diluted) | $3.1K | $45.5K | $175.5K | $2.6M | $8.0M | $15.5M | $19.4M | $27.8M | $61.2M | $109.1M | ||
| Shares Outstanding | $25.9K | $131.4K | $463.5K | $6.7M | $15.1M | $15.9M | $28.3M | $56.3M | $90.8M | $179.6M | ||
| Basic EPS | -- | -- | -- | -- | -- | $-1.34 | $-2.13 | $-1.34 | $-0.50 | $-0.25 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-1.34 | $-2.13 | $-1.34 | $-0.50 | $-0.25 | ||
| Diluted EPS | $-3.5K | $-522 | $-157.5 | $-10.92 | $-2.11 | $-1.34 | $-2.13 | $-1.34 | $-0.50 | $-0.25 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-10.92 | $-2.11 | $-1.34 | $-2.13 | $-1.34 | $-0.50 | $-0.25 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | $675.0K | $13.6M | $8.7M | $16.9M | $20.7M | -- | -- | -- | -- | ||
| Acquired In Process Rn D | -- | -- | -- | $-19.4M | -- | -- | -- | -- | -- | -- | ||
| Development Expense | -- | -- | -- | -- | -- | -- | $10.0M | -- | -- | -- | ||
| Diluted Discontinuous Operations | $-1.9K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | $-16.8M | -- | -- | -- | -- | -- | ||
| Net Income Discontinuous Operations | $-12.4M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Net Operating Interest Income Expense | $-1.2M | $-462.0K | $-266.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | $2.8M | $-1.3M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $-200.0K | $-200.0K | $-300.0K | $-400.0K | $9.6M | $11.3M | $12.6M | $13.9M | $12.4M | $12.3M | ||
| Preferred Stock Dividends | -- | $675.0K | $13.6M | $8.7M | $16.9M | $20.7M | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-200.0K | $-200.0K | $-300.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $4.6M | $15.1M | $12.8M | $9.9M | $9.6M | -- | -- | -- | -- | -- | ||
| Restruct | $-28.4M | $-1.9M | -- | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SLS | $9.18 | +7.0% | 10.14M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get SELLAS Life Sciences Group Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW